Search - tctmd.com

Displaying 1 - 20 of 77

Sort: Relevancy | Date

News Daily News

Bax24: Baxdrostat Successful Again, This Time in Resistant Hypertension

Todd Neale

October 07, 2025

News Opinion Editor's Corner ESC 2025

What’s Going to Be Hot at ESC Congress 2025?

Michael O'Riordan

August 25, 2025

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Daily News

Baxdrostat Shows Promise in Uncontrolled or Resistant Hypertension

L.A. McKeown

July 14, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Daily News

Finerenone Cuts Intensification of Oral Diuretics in Outpatient Setting: FINEARTS-HF

Michael O'Riordan

March 03, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Daily News

‘Disproportionate’ Suicide/Self-Harm Signal With Semaglutide: WHO Database

Michael O'Riordan

August 21, 2024

News Daily News

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Michael O'Riordan

August 19, 2024

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

L.A. McKeown

August 01, 2024

News Daily News

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

Michael O'Riordan

July 26, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2024

Shelley Wood

April 30, 2024

News Daily News

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

L.A. McKeown

February 23, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2023

Shelley Wood

November 30, 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

Shelley Wood

November 07, 2023

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

L.A. McKeown

September 01, 2023

Advertisement

Bax24: Baxdrostat Successful Again, This Time in Resistant Hypertension

What’s Going to Be Hot at ESC Congress 2025?

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

Baxdrostat Shows Promise in Uncontrolled or Resistant Hypertension

What’s Going to Be Hot at ACC 2025?

Finerenone Cuts Intensification of Oral Diuretics in Outpatient Setting: FINEARTS-HF

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

‘Disproportionate’ Suicide/Self-Harm Signal With Semaglutide: WHO Database

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

August 2024 Dispatch for the CV Team

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

TCTMD’s Top 10 Most Popular Stories for April 2024

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

TCTMD’s Top 10 Most Popular Stories for November 2023

What’s Going to Be Hot at AHA 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content